Morgan Stanley analyst Jeffrey Hung raised the firm’s price target on Exelixis to $28 from $26 and keeps an Equal Weight rating on the shares. For Exelixis, the firm’s estimates are above consensus on Cabometyx sales and it also updated its model and year-end estimated share count regarding the $500M stock repurchase program through end of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: